Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PTH Analog Type II Odontoid Fracture
NCT04760782 · David Lunardini · PHASE2 · terminated · last registry update 2024-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated early due to low recruitment rate.” | – | Registry record, David Lunardini |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-29Also stopped (terminated): University of Milano Bicocca, Teriparatide (NCT04669782)
- 2025-07-24Phase 3 first posted: Ascendis Pharma Bone Diseases A/S, Palopegteriparatide Experimental Arm + Palopegteriparatide Control Arm (NCT07081997)
- 2025-06-19Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL056 (56.5μg) + Alendronate (NCT07028320)
- 2025-03-27Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLG2128 + Teriparatide Injection (NCT06898060)
- 2025-02-28Results posted on the registry: Ascendis Pharma Bone Diseases A/S, TransCon PTH + Placebo (NCT04701203)
- 2024-05-01Also stopped (withdrawn): Daniel Horwitz, Abaloparatide + Placebo (NCT04626141)
- 2023-12-04Phase 3 first posted: Pharmbio Korea Co., Ltd., PBK_L2201 + Placebo (NCT06154187)
- 2023-11-22Results posted on the registry: Radius Health, Inc., abaloparatide-sMTS (NCT04366726)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision